Figure 6.

PVT Suppresses the Growth of Orthotopically Implanted Pancreatic Tumors

(A) PANC1-luc cells were orthotopically implanted on the pancreas of athymic nude mice, and after 18 days of tumor implantation, mice were treated with 10mg/kg PVT everyday. Tumor luminescence was measured approximately twice per week and plotted against days (n = 5). Representative images of mice from control and PVT-treated groups at the day of sacrifice. (B) Orthotopic pancreatic tumors were aseptically removed, and the tumor weight was compared between control and PVT-treated groups. (C) Individual tumors from control and PVT-treated groups were imaged for bioluminescence. (D) Excised pancreas/tumors were homogenized, lysed, and analyzed for Gli1, SOX2, NANOG, c-Myc, and cleaved caspase 3 by western blotting. β-Actin was used as a loading control. The protein expression in the control and treatment groups was normalized with the respective β-actin of each group. Each lane of blot represents a tumor from an individual mouse. Individual FFPE pancreas/tumors were processed, sectioned, and analyzed for (E) IHC and (F) TUNEL assays. Scale bars, 200 µm. The statistical significance level was considered to be p ≤ 0.05. ∗p ≤ 0.05.